20 Sep 2023 Vir Biotechnology Announces First Participant Dosed in New Phase 1 Trial Evaluating VIR-1388, an Investigational T Cell Vaccine for the Prevention of HIV
20 Sep 2023 SpyBiotech Announces MHRA Clinical Trial Application Filing for SPYVLP01
19 Sep 2023 LinKinVax and Gustave Roussy Announced First Patient Dosed in Phase I/IIa Clinical Study on HPV.DCVax in HPV-positive Oropharyngeal Cancer
12 Sep 2023 Replicate Bioscience Initiates a Phase 1 Trial of its Next-Generation srRNA Vaccine
12 Sep 2023 OSE Immunotherapeutics Announces: Positive Phase 3 Data from its Cancer Vaccine in Lung Cancer Patients with Resistance to Previous Immunotherapy Published in Annals of Oncology
12 Sep 2023 Pfizer and BioNTech Receive U.S. FDA Approval for 2023-2024 COVID-19 Vaccine
08 Sep 2023 BriaCell Reports Benchmark-Beating Patient Survival and Clinical Benefit in Advanced Metastatic Breast Cancer
08 Sep 2023 VBI Vaccines Announces Dosing of First Patients in Phase 2b Study of VBI-1901 in Recurrent GBM
07 Sep 2023 Vaxart Announces Topline Data from the Phase 2 Challenge Study of its Monovalent Norovirus Vaccine Candidate
06 Sep 2023 VBI Vaccines Partner Brii Biosciences Announces Topline Interim Results of Phase 2 Study Evaluating BRII-179 (VBI-2601) in Combination With PEG-IFNα for the Treatment of Chronic Hepatitis B
05 Sep 2023 Arcturus Therapeutics and CSL Announce European Medicines Agency Validates Marketing Authorization Application for ARCT-154 Vaccine to Prevent COVID-19
05 Sep 2023 ILiAD Biotechnologies Reports First-ever Demonstration of Protection Against B. pertussis Colonization in Phase 2b Human Challenge Study of BPZE1 Vaccine
05 Sep 2023 ACM Biolabs Announces Positive Topline Results from a Phase I Trial of SARS-CoV-2 Booster Vaccine ACM-001
04 Sep 2023 Stallergenes Greer Announces Global Agreement With Nestlé Regarding the Peanut Allergy Oral Immunotherapy Treatment Palforzia®
31 Aug 2023 First Patient with Chronic Hepatitis B Dosed with ISA104 in First-in-Human Phase 1 Study
31 Aug 2023 Pfizer and BioNTech Receive Positive CHMP Opinion for Omicron XBB.1.5-adapted COVID-19 Vaccine in the European Union
25 Aug 2023 Immunomic Therapeutics Doses First Patient in its Phase 1 Clinical Trial of ITI-1001, a pDNA Vaccine for the Treatment of Glioblastoma Multiforme
24 Aug 2023 European Commission Approves Pfizer’s ABRYSVO™ to Help Protect Infants through Maternal Immunization and Older Adults from RSV
22 Aug 2023 U.S. FDA Approves ABRYSVO™, Pfizer’s Vaccine for the Prevention of Respiratory Syncytial Virus (RSV) in Infants Through Active Immunization of Pregnant Individuals 32-36 Weeks of Gestational Age
19 Aug 2023 Moderna Clinical Trial Data Confirm Its Updated COVID-19 Vaccine Generates Robust Immune Response in Humans Against Widely Circulating Variants
09 Aug 2023 Icosavax Reports Positive 12-Month Durability Data for VLP Vaccine Candidate IVX-121 Against RSV and Initial Evidence for Revaccination Potential
09 Aug 2023 Meissa Vaccines Announces Positive Clinical Data for the First RSV Vaccine Designed to Protect Infants and Toddlers
03 Aug 2023 U.S. FDA Approves Merck’s ERVEBO® (Ebola Zaire Vaccine, Live) for Use in Children 12 Months of Age and Older
02 Aug 2023 CureVac Announces Dosing of First Participant in Phase 2 Study of Modified COVID-19 mRNA Vaccine Candidates Developed in Collaboration with GSK
02 Aug 2023 DAICHIRONA® for Intramuscular Injection (Monovalent: Original Strain), mRNA COVID-19 Vaccine, Approved for Manufacturing and Marketing as Booster Vaccination in Japan

La Merie Biologics

FREE Weekly News Bulletin

Sign Up

2022 Sales ofAntibodies & Proteins

New Product Alert

For La Merie Publishing

Sign Up